David Lacomis – Lambert-Eaton Myasthenic Syndrome

Submitted By:
Published Date:
January 25, 2020

Access Program Information

The purpose of the study is to provide expanded access (compassionate use) of 3,4
diaminopyridine to patients with Lambert-Eaton myasthenic syndrome (LEMS).

Rare Disease:
Lambert-Eaton Myasthenic Syndrome